Türkiye'de İleri Evre Küçük Hücreli Dışı Akciğer Kanserinde Pemetrexed ve Gemcitabine Tedavilerinin Maliyet Etkililik Analizi

Abstract

The purpose of the study is to determine the cost effectiveness of the chemotherapy medications that contain gemcitabine and pemetrexed which are used in the first line treatment of advanced non-small cell lung cancer (NSCLC). Within the scope of the study, effectiveness and cost of platinum-based pemetrexed and platinum-based gemcitabine treatments as the first line treatment of advanced NSCLC was evaluated with the use of Markov model and from the perspective of the Social Security Institution. In Markov model, the transitions between the life-long health conditions of advanced NSCLC patients are simulated with the use of cycles of one month.